HMNC Brain Health Appoints Jonas Henningsen as Vice President of Regulatory Affairs

Experienced Regulatory Leader to Drive HMNC’s Precision Psychiatry Programs Toward Key Approvals

Munich, March 25, 2025 – HMNC Brain Health (“HMNC''), a clinical stage precision psychiatry biopharma company, pioneering the development of personalized therapies powered by predictive companion diagnostics, announces the appointment of Jonas Henningsen, M.Sc as Vice President of Regulatory Affairs. With deep experience in regulatory strategy and successful global approval efforts for neuropsychiatric therapies, Mr. Henningsen will oversee regulatory strategy and submissions across HMNC's portfolio.

In his new role, Mr. Henningsen will support advancing key programs such as Nelivabon, an AI-powered oral drug candidate targeting the vasopressin V1b receptor, as well as optimizing study designs and regulatory strategies across the company’s broader portfolio.

“Joining HMNC Brain Health is a timely opportunity, as the demand for innovative, precision-based treatments for depression continues to grow,” said Jonas Henningsen, M.Sc., Vice President of Regulatory Affairs. “Having worked extensively on regulatory strategies for neuropsychiatric treatments, I understand the challenges in bringing these therapies to market. I look forward to leveraging that experience to advance HMNC’s pipeline and help navigate the regulatory path for novel, personalized treatments.”

Most recently, Mr. Henningsen has served as the Vice President of Regulatory, Quality and Project Management at Alligator Bioscience AB, and previously held the role of Head of Regulatory Science at Lundbeck. At Lundbeck, he played a key role in shaping regulatory strategies for several high-profile programs, including brexpiprazole in agitation associated with Alzheimer’s dementia (AAD), schizophrenia, and major depressive disorder (MDD); idalopirdine for Alzheimer’s disease; aripiprazole long-acting injectable for schizophrenia; and escitalopram for depression and anxiety disorders. His extensive knowledge of U.S. and EU regulatory requirements in neuropsychiatric drug development will be instrumental in guiding HMNC’s pipeline programs.

Maximilian Doebler, Chief Business Officer at HMNC Brain Health, added: “Jonas’ deep expertise in regulatory strategy for neuropsychiatric treatments, particularly his experience in bringing therapies for neuropsychiatric disorders through the approval process, makes him an invaluable addition to HMNC. His first-hand experience with global regulatory agencies and late-stage drug development will be critical as we work to advance our precision psychiatry programs toward approval and ultimately deliver better treatment options for patients.”

Jonas Henningsen holds a Master of Science in Pharmacy from the University of Copenhagen and a Diploma in Regulatory Affairs from the University of Wales.

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates. The Company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). The Company has operations in both the US and Germany and is backed by a renowned global VC, several family offices and strategic healthcare investors. The Company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

Media contacts:

Anne Donohoe (U.S.)
+1 212-896-1265
hmnc[at]kcsa[dot]com